Immunotherapy Combinations Poised to Shift Standard of Care in RCC – OncLive
OncLive |
Immunotherapy Combinations Poised to Shift Standard of Care in RCC
OncLive OncLive: Please provide an overview of your presentation at this meeting. Hammers: I discussed immunotherapy combinations. It is an exciting time because it is expected that immunotherapy combinations are going to supplant first-line tyrosine kinase … |
